EPFL spinout Lunaphore has received $2m in a series C extension provided by Swiss Entrepreneurs Fund, adding to an initial $23.6m tranche led by PHC Holdings three months ago.

Satt AxLR-allied Phost'in Therapeutics has secured funding to progress cancer drugs targeting glycosylation and the body's immune system.

Lunaphore has received $2m in a series C extension provided by Swiss Entrepreneurs Fund, adding to an initial $23.6m tranche led by PHC Holdings three months ago.

The valve calcification treatment developer raised the cash from Sofinnova Partners and existing backers that may include Clal Biotechnology Industries.

Return investor SBCVC contributed to a round that took the total raised by the cancer screening system developer past the $130m mark.

Paige.ai has now raised $75m to date, with the latest funding set to help refine its cancer pathology software offering.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Utimco-backed accountable care services network Aledade attracted GV and Echo Health Ventures for its latest round.

GV took part in a series C round for accountable care services network Aledade that also attracted fellow corporate venturing unit Echo Health Ventures.

Huntington's disease therapy developer BrainVectis, a spinout of research institute Inserm, has been acquired having disclosed just $1m of equity funding in 2016.